|
ChemicalBook Optimization Suppliers |
|
| | (4S)-2,6-ジオキソヘキサヒドロピリミジン-4-カルボン酸 製品概要 |
| 化学名: | (4S)-2,6-ジオキソヘキサヒドロピリミジン-4-カルボン酸 | | 英語化学名: | L-DIHYDROOROTIC ACID | | 别名: | L-DIHYDROOROTIC ACID;(S)-2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid;2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid;L-4,5-Dihydroorotic acid~(S)-(+)-2,6-Dioxohexahydro-4-pyrimidinecarboxylic acid;(S)-(+)-HYDROOROTIC ACID;(4S)-2,6-dioxo-1,3-diazinane-4-carboxylic acid;L-4,5-dihydroorotic acid;(S)-4,5-dihydroorotate | | CAS番号: | 5988-19-2 | | 分子式: | C5H6N2O4 | | 分子量: | 158.11 | | EINECS: | 624-952-7 | | カテゴリ情報: | Heterocycles;Miscellaneous Biochemicals;Amino Acid Derivatives;5988-19-2 | | Mol File: | 5988-19-2.mol |  |
| | (4S)-2,6-ジオキソヘキサヒドロピリミジン-4-カルボン酸 物理性質 |
| 融点 | 254-255 °C (dec.)(lit.) | | 沸点 | 283.16°C (rough estimate) | | 比重(密度) | 1.523 | | 屈折率 | 1.5090 (estimate) | | 貯蔵温度 | Sealed in dry,2-8°C | | 溶解性 | DMSO (Slightly), Water (Slightly, Heated, Sonicated) | | 酸解離定数(Pka) | 2.82±0.20(Predicted) | | 外見 | Powder | | 色 | White to off-white | | 水溶解度 | Soluble in water (partly), and dimethyl formamide. | | InChIKey | UFIVEPVSAGBUSI-REOHCLBHSA-N | | CAS データベース | 5988-19-2(CAS DataBase Reference) | | NISTの化学物質情報 | Orotic acid, dihydro-, l-(5988-19-2) |
| | (4S)-2,6-ジオキソヘキサヒドロピリミジン-4-カルボン酸 Usage And Synthesis |
| 化学的特性 | White to off-white crystalline powder | | 使用 | L-Dihydroorotic acid a metabolite. | | 定義 | ChEBI: (S)-dihydroorotic acid is the (S)-enantiomer of dihydroorotic acid that is an intermediate in the metabolism of pyridine. It has a role as a Saccharomyces cerevisiae metabolite, a human metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a conjugate acid of a (S)-dihydroorotate. It is an enantiomer of a (R)-dihydroorotic acid. | | Biochem/physiol Actions | L-Dihydroorotic acid (DHO) serves as a substrate for dihydroorotate dehydrogenase (DHODH), an enzyme in the de novo synthesis of pyrimidine. Inhibition of DHOH by its inhibitors causes a large accumulation of upstream metabolite DHO and a reduction in the uridine levels. Therefore, DHO and uridine can be used as biomarkers for pyrimidine synthesis for the clinical development of DHOH inhibitors. |
|